Methadone in chronic non-cancer pain: rotation from other opioids and choice of dose

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-005035-26-SE

Enrollment

Registered

2005-02-11

Start date

2005-04-05

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic non-cancer pain

Interventions

Trade Name: Methadone Product Name: Metadon Pharmaceutical Form: Tablet INN or Proposed INN: Methadone hydrochloride Concentration unit: mg milligram(s) Concentration type: equal

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic non cancer pain which has responded poorly to other opioids than methadone Men and women older than 18 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Impossibility to take oral medication Renal or liver functional impairment Difficulties in communication Cognitive impairment Use of other medicinal products which will not be combined with methadone (se protocol) Pregnancy(prevention according to agreement with the patient)

Design outcomes

Primary

Measure	Time frame
Main Objective: To find out if you can predict the dose methadone needed for good pain relief based on the dose of the previoud opioid and genetic metabolic pattern;Secondary Objective: To evaluate the benefits of methadone treatment in long trem treatment of chronic non malignant pain;Primary end point(s): Pharmacokinetic study	—

Countries

Sweden

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026